CA3133830A1 - Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins - Google Patents

Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins Download PDF

Info

Publication number
CA3133830A1
CA3133830A1 CA3133830A CA3133830A CA3133830A1 CA 3133830 A1 CA3133830 A1 CA 3133830A1 CA 3133830 A CA3133830 A CA 3133830A CA 3133830 A CA3133830 A CA 3133830A CA 3133830 A1 CA3133830 A1 CA 3133830A1
Authority
CA
Canada
Prior art keywords
chimeric protein
cancer
seq
mutations
signaling agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3133830A
Other languages
English (en)
French (fr)
Inventor
Nikolai Kley
Jan Tavernier
Alexander VAN PARYS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Orionis Biosciences Inc
Original Assignee
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Orionis Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent, Vlaams Instituut voor Biotechnologie VIB, Orionis Biosciences Inc filed Critical Universiteit Gent
Publication of CA3133830A1 publication Critical patent/CA3133830A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3133830A 2019-03-28 2020-03-27 Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins Pending CA3133830A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825579P 2019-03-28 2019-03-28
US62/825,579 2019-03-28
PCT/US2020/025419 WO2020198659A1 (en) 2019-03-28 2020-03-27 Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins

Publications (1)

Publication Number Publication Date
CA3133830A1 true CA3133830A1 (en) 2020-10-01

Family

ID=72608957

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3133830A Pending CA3133830A1 (en) 2019-03-28 2020-03-27 Fms-like tyrosine kinase 3 ligand (flt3l)-based chimeric proteins

Country Status (6)

Country Link
US (1) US20220185857A1 (https=)
EP (1) EP3946409A4 (https=)
JP (2) JP7749186B2 (https=)
CN (1) CN113645988A (https=)
CA (1) CA3133830A1 (https=)
WO (1) WO2020198659A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
CN114606227B (zh) * 2022-02-22 2024-03-08 复旦大学 高精度腺嘌呤碱基编辑器及其应用
AU2024341598A1 (en) * 2023-09-12 2026-04-23 Heligenics Inc. Engineered interferon-beta proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US20020034517A1 (en) * 1995-10-04 2002-03-21 Kenneth Brasel Dendritic cell stimulatory factor
PL333023A1 (en) * 1996-10-25 1999-11-08 Searle & Co Chimerical antagonists of haeomogenic multifunctional receptors
US6660257B1 (en) * 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
JP2007515946A (ja) 2003-06-13 2007-06-21 オンコマックス アクイジション コーポレイション 抗腫瘍二元機能融合タンパク質の調製および適用
ES2694180T3 (es) * 2012-01-20 2018-12-18 Vib Vzw Citocinas de haz alfa-helicoidal mutantes dirigidas
WO2015168474A1 (en) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
JP6898325B2 (ja) * 2015-12-08 2021-07-07 ユニバーシティ−インダストリー・ファンデーション・ヨンセイ・ユニバーシティ ＧＭ−ＣＳＦ遺伝子；Ｆｌｔ３Ｌ−ＴＲＡＩＬ融合遺伝子；ＴＧＦ−βの発現を抑制するｓｈＲＮＡ；およびＨＳＰ発現を抑制するｓｈＲＮＡを含む抗腫瘍組成物
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies

Also Published As

Publication number Publication date
CN113645988A (zh) 2021-11-12
WO2020198659A1 (en) 2020-10-01
EP3946409A4 (en) 2023-06-21
JP2025111546A (ja) 2025-07-30
JP7749186B2 (ja) 2025-10-06
EP3946409A1 (en) 2022-02-09
US20220185857A1 (en) 2022-06-16
JP2022527322A (ja) 2022-06-01

Similar Documents

Publication Publication Date Title
EP3411398B1 (en) Targeted therapeutic agents and uses thereof
US20220177550A1 (en) Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3)
US12497436B2 (en) Chimeric protein, and encoding nucleic acid thereof, comprising interferon-β and a targeting moiety comprising a single-domain antibody or single-chain antibody
US12527843B2 (en) Immune-cell targeted bispecific chimeric proteins and uses thereof
JP2025111546A (ja) Ｆｍｓ様チロシンキナーゼ３リガンド（ｆｌｔ３ｌ）ベースキメラタンパク質
US20110293555A1 (en) Tumor necrosis factor-alpha mutants
US20230399406A1 (en) Targeted therapeutic agents and uses thereof
AU2020270046B2 (en) Alkaline phosphate-based oncology treatments
AU2022221434A1 (en) Therapeutic multi-targeting constructs and uses thereof
US20210198319A1 (en) Cytotoxic peptides and conjugates thereof
HK40116401A (en) Targeted therapeutic agents and uses thereof
EP4717277A1 (en) Use of drug conjugate in treating tumor disease and method therefor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240326

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250317

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250317

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250917

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260115

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260127

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260127

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260316

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260316